Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer-Reference-Cited by-同舟云学术

Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer

Published:2014 Issue:4 Volume:5 Page:646
ISSN:2218-4333
Container-title:World Journal of Clinical Oncology
language:en
Short-container-title:WJCO

Author:

Asami Kazuhiro

Publisher

Baishideng Publishing Group Inc.

Subject

Oncology

Reference66 articles.

1. The EGF receptor family: spearheading a merger of signaling and therapeutics

2. The role of the EGFR signaling in tumor microenvironment

3. Regulation of EGF-receptor expression by EGF and TGFα in epidermoid cancer cells is cell type-specific

4. Amann J, Kalyankrishna S, Massion PP, Ohm JE, Girard L, Shigematsu H, Peyton M, Juroske D, Huang Y, Stuart Salmon J. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 2005;65:226-235.

5. Epidermal growth factor receptor mutations in lung cancer

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications;Cells;2023-12-25

2. Design and synthesis of gefitinib derivatives as potential drugs for cancer treatment: antiproliferative activity, molecular docking, and ADMET prediction;Letters in Drug Design & Discovery;2023-08-10

3. Construction and Verification of a Combined Hypoxia and Immune Index for Clear Cell Renal Cell Carcinoma;Frontiers in Genetics;2022-02-09

4. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer;Respiratory Research;2020-08-10

5. SNHG14 confers gefitinib resistance in non-small cell lung cancer by up-regulating ABCB1 via sponging miR-206-3p;Biomedicine & Pharmacotherapy;2019-08